At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Ketamine +1 moredrug
Likely dose
Ketamine 0.5mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Extending Ketamine's Effects in Obsessive-Compulsive Disorder (OCD) With Exposure and Response Prevention (EX/RP)
In Brief
A Phase 2 clinical trial evaluating Ketamine and Exposure and Response Prevention for Obsessive-Compulsive Disorder. Completed, enrolled 10 participants across 1 site.
Detailed Summary
This study investigates if a single dose of IV Ketamine can rapidly improve Obsessive-Compulsive Disorder (OCD) symptoms and whether these effect can be maintained with a condensed course of a type of Cognitive Behavioral Therapy called Exposure and Response Prevention (EX/RP). You will be compensated for your time and travel. Participants must be between the ages of 18-55.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder
CountriesUnited States
CollaboratorsNational Institute of Mental Health (NIMH)
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartDec 2013
First PostedFeb 2014
Primary CompletionDec 2015
TodayJul 2026
First PostedFeb 14, 2014
Enrollment StartDec 1, 2013
Primary CompletionDec 1, 2015
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 12.4 years ago
Interventions
Ketaminedrug
0.5mg/kg IV
Exposure and Response Preventionbehavioral
A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.